Autoantibodies in COVID-19: Pathogenic Mechanisms and Implications for Severe Illness and Post-Acute Sequelae
Authors:
- Lais Alves Do-NascimentoLDLais Alves Do-Nascimento
- Nicolle Rakanidis MachadoNMNicolle Rakanidis Machado
- Isabella Siuffi BergamascoIBIsabella Siuffi Bergamasco
- João Vitor da Silva BorgesJBJoão Vitor da Silva Borges
- Fabio da Ressureição SgnottoFSFabio da Ressureição Sgnotto
- Jefferson Russo VictorJVJefferson Russo Victor
Open Access
Abstract
The COVID-19 pandemic, caused by SARS-CoV-2, has led to a wide range of acute and chronic disease manifestations. While most infections are mild, a significant number of patients develop severe illness marked by respiratory failure, thromboinflammation, and multi-organ dysfunction. In addition, post-acute sequelae—commonly known as long-COVID—can persist for months. Recent studies have identified the emergence of diverse autoantibodies in COVID-19, including those targeting nuclear antigens, phospholipids, type I interferons, cytokines, endothelial components, and G-protein-coupled receptors. These autoantibodies are more frequently detected in patients with moderate to severe disease and have been implicated in immune dysregulation, vascular injury, and persistent symptoms. This review examines the underlying immunological mechanisms driving autoantibody production during SARS-CoV-2 infection—including molecular mimicry, epitope spreading, and bystander activation—and discusses their functional roles in acute and post-acute disease. We further explore the relevance of autoantibodies in maternal–fetal immunity and comorbid conditions such as autoimmunity and cancer, and we summarize current and emerging therapeutic strategies. A comprehensive understanding of SARS-CoV-2-induced autoantibodies may improve risk stratification, inform clinical management, and guide the development of targeted immunomodulatory therapies.Keywords
Funding Information
- Laboratory of Medical Investigation 56 (LIM-56), Faculty of Medicine, University of São Paulo (302937/2021-8, 402406/2024-9, 2021/08225-8, 2023/16782-0)
- National Council for Scientific and Technological Development (CNPq) (302937/2021-8, 402406/2024-9, 2021/08225-8, 2023/16782-0)
- Sao Paulo Research Foundation (FAPESP) (302937/2021-8, 402406/2024-9, 2021/08225-8, 2023/16782-0)
This publication has 113 references indexed in Scilit:
- Mechanistic Insights Into Long Covid: Viral Persistence, Immune Dysregulation, and Multi‐Organ DysfunctionComprehensive Physiology, 2025
- T-cell immunobiology and cytokine storm of COVID-192025
- An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extensionActa Biomaterialia, 2022
- COVID-19 and cancer: start the resolution!Cancer and Metastasis Reviews, 2022
- Neutralizing Autoantibodies to Type I IFNs in >10% of Patients with Severe COVID-19 Pneumonia Hospitalized in Madrid, SpainJournal of Clinical Immunology, 2021
- Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 PneumoniaJournal of Clinical Immunology, 2021
- Antiphospholipid Antibodies in Critically Ill Patients With COVID‐19Arthritis & Rheumatology, 2020
- IgG from Non-atopic Individuals Induces In Vitro IFN-γ and IL-10 Production by Human Intra-thymic γδT Cells: A Comparison with Atopic IgG and IVIgArchivum Immunologiae et Therapiae Experimentalis, 2019
- Preconceptional allergen immunization can induce offspring IL-17 secreting B cells (B17): do they share similarities with regulatory B10 cells?Allergologia et Immunopathologia, 2018
- Characterizing the Pattern of Anomalies in Congenital Zika Syndrome for Pediatric CliniciansJAMA Pediatrics, 2017